311 related articles for article (PubMed ID: 23873720)
1. RAS mutations in thyroid cancer.
Howell GM; Hodak SP; Yip L
Oncologist; 2013; 18(8):926-32. PubMed ID: 23873720
[TBL] [Abstract][Full Text] [Related]
2. Well differentiated follicular thyroid neoplasia: impact of molecular and technological advances on detection, monitoring and treatment.
Gianoukakis AG; Giannelli SM; Salameh WA; McPhaul LW
Mol Cell Endocrinol; 2011 Jan; 332(1-2):9-20. PubMed ID: 21094678
[TBL] [Abstract][Full Text] [Related]
3. Detection of RAS mutation by pyrosequencing in thyroid cytology samples.
Guerra A; Carrano M; Angrisani E; Puzziello A; Izzo G; Di Crescenzo V; Vatrella A; Vitale M
Int J Surg; 2014; 12 Suppl 1():S91-4. PubMed ID: 24866065
[TBL] [Abstract][Full Text] [Related]
4. ROLE OF MOLECULAR MARKERS IN THYROID NODULE MANAGEMENT: THEN AND NOW.
Nikiforov YE
Endocr Pract; 2017 Aug; 23(8):979-988. PubMed ID: 28534687
[TBL] [Abstract][Full Text] [Related]
5. Utilities of
Guan H; Toraldo G; Cerda S; Godley FA; Rao SR; McAneny D; Doherty G; Braverman L; Lee SL
Thyroid; 2020 Apr; 30(4):536-547. PubMed ID: 31996097
[No Abstract] [Full Text] [Related]
6. Predicting malignancy in thyroid nodules: molecular advances.
Melck AL; Yip L
Head Neck; 2012 Sep; 34(9):1355-61. PubMed ID: 21818817
[TBL] [Abstract][Full Text] [Related]
7. Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations-a meta-analysis.
Vuong HG; Altibi AM; Duong UN; Ngo HT; Pham TQ; Tran HM; Oishi N; Mochizuki K; Nakazawa T; Hassell L; Katoh R; Kondo T
Tumour Biol; 2017 Oct; 39(10):1010428317713913. PubMed ID: 29037127
[TBL] [Abstract][Full Text] [Related]
8. Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics.
Radkay LA; Chiosea SI; Seethala RR; Hodak SP; LeBeau SO; Yip L; McCoy KL; Carty SE; Schoedel KE; Nikiforova MN; Nikiforov YE; Ohori NP
Cancer Cytopathol; 2014 Dec; 122(12):873-82. PubMed ID: 25132659
[TBL] [Abstract][Full Text] [Related]
9. Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules.
Beaudenon-Huibregtse S; Alexander EK; Guttler RB; Hershman JM; Babu V; Blevins TC; Moore P; Andruss B; Labourier E
Thyroid; 2014 Oct; 24(10):1479-87. PubMed ID: 24811481
[TBL] [Abstract][Full Text] [Related]
10. Genetic Alterations in Hungarian Patients with Papillary Thyroid Cancer.
Tobiás B; Halászlaki C; Balla B; Kósa JP; Árvai K; Horváth P; Takács I; Nagy Z; Horváth E; Horányi J; Járay B; Székely E; Székely T; Győri G; Putz Z; Dank M; Valkusz Z; Vasas B; Iványi B; Lakatos P
Pathol Oncol Res; 2016 Jan; 22(1):27-33. PubMed ID: 26259532
[TBL] [Abstract][Full Text] [Related]
11. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma.
An JH; Song KH; Kim SK; Park KS; Yoo YB; Yang JH; Hwang TS; Kim DL
Clin Endocrinol (Oxf); 2015 May; 82(5):760-6. PubMed ID: 25109485
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation profiling of well-differentiated thyroid cancer uncovers markers of recurrence free survival.
Mancikova V; Buj R; Castelblanco E; Inglada-Pérez L; Diez A; de Cubas AA; Curras-Freixes M; Maravall FX; Mauricio D; Matias-Guiu X; Puig-Domingo M; Capel I; Bella MR; Lerma E; Castella E; Reverter JL; Peinado MÁ; Jorda M; Robledo M
Int J Cancer; 2014 Aug; 135(3):598-610. PubMed ID: 24382797
[TBL] [Abstract][Full Text] [Related]
13. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
[TBL] [Abstract][Full Text] [Related]
14. Papillary Thyroid Cancer: Genetic Alterations and Molecular Biomarker Investigations.
Abdullah MI; Junit SM; Ng KL; Jayapalan JJ; Karikalan B; Hashim OH
Int J Med Sci; 2019; 16(3):450-460. PubMed ID: 30911279
[TBL] [Abstract][Full Text] [Related]
15. Molecular genetics and diagnosis of thyroid cancer.
Nikiforov YE; Nikiforova MN
Nat Rev Endocrinol; 2011 Aug; 7(10):569-80. PubMed ID: 21878896
[TBL] [Abstract][Full Text] [Related]
16. RAS Mutations, and RET/PTC and PAX8/PPAR-gamma Chromosomal Rearrangements Are Also Prevalent in Benign Thyroid Lesions: Implications Thereof and A Systematic Review.
Najafian A; Noureldine S; Azar F; Atallah C; Trinh G; Schneider EB; Tufano RP; Zeiger MA
Thyroid; 2017 Jan; 27(1):39-48. PubMed ID: 27750019
[TBL] [Abstract][Full Text] [Related]
17. Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis.
Park SJ; Sun JY; Hong K; Kwak JY; Kim EK; Chung WY; Choi JR
Clin Chem Lab Med; 2013 Aug; 51(8):1673-80. PubMed ID: 23585181
[TBL] [Abstract][Full Text] [Related]
18. Mutation profiles of follicular thyroid tumors by targeted sequencing.
Duan H; Liu X; Ren X; Zhang H; Wu H; Liang Z
Diagn Pathol; 2019 May; 14(1):39. PubMed ID: 31077238
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of genetic mutations in thyroid cancer: a meta-analysis.
Pak K; Suh S; Kim SJ; Kim IJ
Thyroid; 2015 Jan; 25(1):63-70. PubMed ID: 25244593
[TBL] [Abstract][Full Text] [Related]
20. [The advances of molecular pathology of follicular thyroid carcinoma].
Zhan Y; Cui QC
Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):268-70. PubMed ID: 15256127
[No Abstract] [Full Text] [Related]
[Next] [New Search]
